Skip to main content
Terug
Watch Compare

Lyell Immunopharma, Inc.

Datakwaliteit: 100%
LYEL
Nasdaq Manufacturing Chemicals
€ 22,39
▼ € 1,46 (-6,12%)
Marktkapitalisatie: 556,62 M
Prijs
€ 23,86
Marktkapitalisatie
556,62 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -75,89% annually over 5 years
Negative free cash flow of -150,80 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 34,91%
Capital intensive — 2166,67% of revenue goes to capex

Groei

Revenue Growth (5Y)
-75,89%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-40,98%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-87,40%
Onder sectorgemiddelde (-53,34%)
ROIC-58,74%
Net Margin-762355,56%
Op. Margin-748344,44%

Veiligheid

Debt / Equity
N/A
Current Ratio10,30
Interest CoverageN/A

Waardering

PE (TTM)
-2,03
Onder sectorgemiddelde (-1,47)
P/B Ratio1,69
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -2,0 -1,5
P/B 1,7 1,6
ROE % -87,4 -53,3
Net Margin % -762355,6 -41,5
Rev Growth 5Y % -75,9 1,8
D/E — 0,3

Koersdoel Analisten

4 analisten
Buy
Huidig
€ 22,39
+45.2%
Koersdoel
€ 32,50
€ 12,00
€ 36,50
€ 45,00
Vooruitzicht
Forward WPA -€ 9,02
Omzet Sch. 2,51 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 9,02
-€ 11,69 – -€ 7,54
 2,51 M 4
FY2026 -€ 9,41
-€ 11,27 – -€ 8,28
 11.500,0 5

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 2,23 -€ 7,68 -244,1%
Q32025 -€ 2,64 -€ 2,13 +19,4%
Q22025 -€ 3,58 -€ 2,89 +19,4%
Q12025 -€ 3,60 -€ 3,60 0,0%

ETFs Holding This Stock

CNCR CNCR
1,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -40,98% Revenue Growth (3Y) -47,38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -75,89% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 36.000,0 Net Income (TTM) -274,45 M
ROE -87,40% ROA -69,18%
Gross Margin N/A Operating Margin -748344,44%
Net Margin -762355,56% Free Cash Flow (TTM) -150,80 M
ROIC -58,74% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,30
Interest Coverage N/A Asset Turnover 0,00
Working Capital 296,32 M Tangible Book Value 329,12 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,03 Forward P/E N/A
P/B Ratio 1,69 P/S Ratio 15461,54
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -27,09%
Market Cap 556,62 M Enterprise Value 433,04 M
Per Share
EPS (Diluted TTM) -16,06 Revenue / Share 0,00
FCF / Share -6,46 OCF / Share -6,43
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2166,67% FCF Conversion 54,95%
SBC-Adj. FCF -174,69 M Growth Momentum 34,91

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 36.000,0 61.000,0 130.000,0 84,68 M 10,65 M
Net Income -274,45 M -342,99 M -234,63 M -183,12 M -250,22 M
EPS (Diluted) -16,06 -1,31 -0,93 -0,74 -1,84
Gross Profit — — — — —
Operating Income -269,40 M -358,76 M -247,01 M -187,06 M -214,78 M
EBITDA — — — — —
R&D Expenses — — 182,95 M 159,19 M 138,69 M
SG&A Expenses — — — — —
D&A 11,54 M 19,63 M 20,25 M 18,02 M 13,62 M
Interest Expense — — — — —
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 340,05 M 490,86 M 750,03 M 937,56 M 1,13 B
Total Liabilities 91,85 M 108,04 M 95,08 M 104,31 M 197,62 M
Shareholders' Equity 248,20 M 382,82 M 654,95 M 833,25 M 929,79 M
Total Debt — — — — —
Cash & Equivalents 60,18 M 105,60 M 145,65 M 123,55 M 293,83 M
Current Assets 260,94 M 379,59 M 554,69 M 651,30 M 626,29 M
Current Liabilities 49,41 M 53,79 M 34,52 M 37,03 M 46,74 M